Nektar Therapeutics is a research-based development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, autoimmune disease and chronic pain. We leverage Nektar’s proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options. The company’s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company’s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. [Read More]
Topas Therapeutics (Hamburg, Germany) is focused on developing products in areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology induces antigen-specific regulatory T cells in the liver by mimicking bloodborne antigens via the Company´s proprietary peptide-loaded nanoparticles. Topas has programs in MS, T1D and an orphan indication, which is planned to enter the clinic in 2019. The Company has collaborations with Eli Lilly and Company and with Evotec.
Orion BioScience Inc. is an preclinical stage biotechnology company focused on developing our “Soluble Antigen Array’ (or SAgA) technology to intercept and prevent the onset of autoimmune diseases in at risk and early stage patients. Our research into treating multiple sclerosis, neuromyelitis optica, and type-1 diabetes has shown that Orion can develop disease specific immunotherapeutics that can re-tolerize and restore the healthy immune state. The Orion team leverages extensive development experience, and strong clinical relationships, to rapidly progress first-in-class, blockbuster treatments for NMO and T1D into the clinic.